Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Squamous intraepithelial lesion

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

  • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).


    The EU Clinical Trials Register currently displays   44336   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    17 result(s) found for: Squamous intraepithelial lesion. Displaying page 1 of 1.
    EudraCT Number: 2008-007763-16 Sponsor Protocol Number: 1.0 Start Date*: 2009-05-06
    Sponsor Name:Medizinische Universität Wien, Univ.Klinik f.Frauenheilkunde,Abt. f.Gynäkologie und Gyn.Onkologie
    Full Title: Topical Imiquimod in Treating Patients with Grade 2/3 Cervical Intraepithelial Neoplasia
    Medical condition: Grade 2/3 Cervical Intraepithelial Neoplasia
    Disease: Version SOC Term Classification Code Term Level
    9.1 10049701 Cervical intraepithelial neoplasia II LLT
    9.1 10049702 Cervical intraepithelial neoplasia III LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: AT (Completed)
    Trial results: View results
    EudraCT Number: 2008-006946-24 Sponsor Protocol Number: NV25025 Start Date*: 2009-12-10
    Sponsor Name:F. Hoffmann-La Roche Ltd
    Full Title: A randomized, double blind, placebo controlled, parallel group, multicenter study of the safety and response rate of 3 subcutaneously administered doses of 5x10E7pfu RO5217790 in patients with high...
    Medical condition: High grade cervical intraepithelial neoplasia grade 2 or 3 associated with High Risk HPV infection
    Disease: Version SOC Term Classification Code Term Level
    9.1 10049701 Cervical intraepithelial neoplasia II LLT
    9.1 10049702 Cervical intraepithelial neoplasia III LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: DE (Prematurely Ended) FI (Completed) ES (Completed) BE (Completed)
    Trial results: Removed from public view
    EudraCT Number: 2008-004604-31 Sponsor Protocol Number: PCCE201/08 Start Date*: 2008-10-28
    Sponsor Name:Photocure ASA
    Full Title: A randomized phase II dose-finding study of hexaminolevulinate (HAL) photodynamic therapy (PDT) in patients with low-grade cervical intraepithelial neoplasia.
    Medical condition: Low grade cervical intraepithelial neoplasia (CIN)
    Disease: Version SOC Term Classification Code Term Level
    9.1 10066238 Cervical low grade squamous intraepithelial lesion LLT
    Population Age: Adults Gender: Female
    Trial protocol: DE (Completed) FR (Completed)
    Trial results: View results
    EudraCT Number: 2020-001342-19 Sponsor Protocol Number: YHGT-CEV-R1 Start Date*: 2020-11-13
    Sponsor Name:Asieris MediTech Co., Ltd.
    Full Title: A double blind, prospective, randomized, placebo controlled, multi-center phase 3 study to evaluate efficacy and safety of Cevira® in patients with cervical histologic high-grade squamous intraepit...
    Medical condition: Patients with cervical histologic HSIL.
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004872 10064455 HSIL LLT
    Population Age: Adults Gender: Female
    Trial protocol: HU (Completed) DE (Completed) SK (Completed) PL (Completed) NL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2007-005230-37 Sponsor Protocol Number: HPV01/01 Start Date*: 2008-04-02
    Sponsor Name:Leiden University Medical Center
    Full Title: Randomised Controlled Study on the Effects of Imiquimod, a TLR 7 Activating Agent, on the HPV16-Specific Immune Response Following HPV16 E6/E7 Synthetic Long Peptides Vaccination in Women with HPV1...
    Medical condition: Adult female patients, with histological evidence of Vulvar intraepithelial neoplasia (VIN) grade III lesions of the squamous cell type, positive for HPV (Human Papilloma Virus)16.
    Disease: Version SOC Term Classification Code Term Level
    9.1 10056574 Vulval intraepithelial neoplasia LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: NL (Temporarily Halted)
    Trial results: (No results available)
    EudraCT Number: 2010-023903-91 Sponsor Protocol Number: PCCE203/10 Start Date*: Information not available in EudraCT
    Sponsor Name:Photocure ASA
    Full Title: A randomized phase II dose-finding study of hexaminolevulinate (HAL) photodynamic therapy (PDT) in patients with low/moderate-grade cervical intraepithelial neoplasia (CIN1 or 2).
    Medical condition: Patients with low/moderate-grade cervical intraepithelial neoplasia (CIN1 or 2).
    Disease: Version SOC Term Classification Code Term Level
    14.1 10038604 - Reproductive system and breast disorders 10066238 Cervical low grade squamous intraepithelial lesion LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: DE (Completed) SK (Completed) CZ (Completed)
    Trial results: View results
    EudraCT Number: 2019-000318-12 Sponsor Protocol Number: MITOCERV3 Start Date*: 2020-02-20
    Sponsor Name:FONDAZIONE POLICLINICO UNIVERSITARIO AGOSTINO GEMELLI IRCCS UNIVERSITA' CATTOLICA DEL SACRO CUORE
    Full Title: MITO CERV 3:Phase II study on Carboplatin-Paclitaxel-Pembrolizumab in neoadjuvant treatment of locally advanced cervical cancer
    Medical condition: Locally advanced cervical cancer.
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004864 10007494 Carcinoma uterine cervix in situ LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2018-004114-17 Sponsor Protocol Number: HPV-303 Start Date*: Information not available in EudraCT
    Sponsor Name:Inovio Pharmaceuticals, Inc.
    Full Title: REVEAL 2: A Prospective, Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of VGX-3100 Delivered Intramuscularly Followed by Electroporation with CELLECTRA™ 5PSP for the Treatment of HPV-1...
    Medical condition: HPV-16 and/or HPV-18 related high grade squamous intraepithelial lesion (HSIL) of the cervix
    Disease: Version SOC Term Classification Code Term Level
    20.1 10022891 - Investigations 10064328 Human papilloma virus test positive PT
    20.0 100000004872 10066237 Cervical high grade squamous intraepithelial lesion LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: GB (GB - no longer in EU/EEA) LT (Completed) EE (Completed) ES (Restarted) PL (Completed) FI (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2016-000870-39 Sponsor Protocol Number: CHDR1607 Start Date*: 2017-08-21
    Sponsor Name:Cutanea Life Sciences
    Full Title: A phase 2, randomized, vehicle-controlled, double-blind study to explore the efficacy, pharmacodynamics and safety of topical ionic contra-viral therapy (ICVT) comprised of digoxin and furosemide i...
    Medical condition: HPV-induced genital lesions of immunocompromised and immunocompetent patients
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000016515 10018182 Genital warts LLT
    20.0 100000024086 10064455 HSIL LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: NL (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2016-002761-63 Sponsor Protocol Number: HPV-301 Start Date*: 2018-04-16
    Sponsor Name:Inovio Pharmaceuticals, Inc.
    Full Title: A PROSPECTIVE, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 3 STUDY OF VGX-3100 DELIVERED INTRAMUSCULARLY FOLLOWED BY ELECTROPORATION WITH CELLECTRA™ 5PSP FOR THE TREATMENT OF HPV-16 AND/OR H...
    Medical condition: HPV-16 AND/OR HPV-18 RELATED HIGH GRADE SQUAMOUS INTRAEPITHELIAL LESIONS (HSIL) OF THE CERVIX
    Disease: Version SOC Term Classification Code Term Level
    21.1 10022891 - Investigations 10064328 Human papilloma virus test positive PT
    21.1 100000004872 10066237 Cervical high grade squamous intraepithelial lesion LLT
    Population Age: Adults Gender: Female
    Trial protocol: GB (GB - no longer in EU/EEA) LT (Completed) FI (Completed) DE (Completed) CZ (Prematurely Ended) ES (Completed) PT (Completed) PL (Completed) SK (Completed) BE (Completed) NL (Ongoing) EE (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2014-002336-14 Sponsor Protocol Number: Start Date*: 2014-09-05
    Sponsor Name:University Hosptial Bristol NHS Foundation trust
    Full Title: A phase II study of Cabazitaxel chemotherapy in relapsed locally advanced and/or metastatic carcinoma of the penis.
    Medical condition: Relapsed, locally advanced and/or metastatic carcinoma of the penis.
    Disease: Version SOC Term Classification Code Term Level
    17.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10007384 Carcinoma in situ of penis PT
    Population Age: Adults Gender: Male
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2018-001269-18 Sponsor Protocol Number: VMT-VT-1161-CL-011 Start Date*: 2019-03-13
    Sponsor Name:Mycovia Pharmaceuticals, Inc
    Full Title: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of VT-1161 Oral Capsules in the Treatment of Subjects with Recurrent Vulvovaginal Candidiasis
    Medical condition: Recurrent Vulvovaginal Candidiasis
    Disease: Version SOC Term Classification Code Term Level
    20.1 10021881 - Infections and infestations 10047784 Vulvovaginal candidiasis PT
    Population Age: Adolescents, Under 18, Adults Gender: Female
    Trial protocol: BG (Completed) PL (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2008-008124-33 Sponsor Protocol Number: 112024 Start Date*: 2009-10-07
    Sponsor Name:GlaxoSmithKline Biologicals
    Full Title: A phase IIIb, open, multi centre gynaecological extension study for follow-up of a subset of 580299/008 study subjects who were either cervical cytology negative and oncogenic HPV positive or pregn...
    Medical condition: GSK Biologicals’ HPV-16/18 L1 VLP AS04 vaccine is indicated in females from 10 years of age onwards for the prevention of cervical cancer (squamous-cell carcinoma and adenocarcinoma) by protecting ...
    Disease:
    Population Age: Adults Gender: Female
    Trial protocol: FI (Completed) ES (Completed) DE (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2018-001270-26 Sponsor Protocol Number: VMT-VT-1161-CL-012 Start Date*: 2018-12-12
    Sponsor Name:Mycovia Pharmaceuticals, Inc
    Full Title: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of VT-1161 Oral Capsules in the Treatment of Subjects with Recurrent Vulvovaginal Candidiasis
    Medical condition: Recurrent Vulvovaginal Candidiasis
    Disease: Version SOC Term Classification Code Term Level
    20.1 10021881 - Infections and infestations 10047784 Vulvovaginal candidiasis PT
    Population Age: Adolescents, Under 18, Adults Gender: Female
    Trial protocol: CZ (Completed) BE (Completed) HU (Completed)
    Trial results: View results
    EudraCT Number: 2021-004579-16 Sponsor Protocol Number: FU-04-21 Start Date*: 2022-01-18
    Sponsor Name:Adamed Pharma S.A.
    Full Title: A Phase II, Randomized, Parallel design, Open label, Dose ranging Study to evaluate the efficacy and safety of Furazidin vaginal tablets in women with bacterial vaginosis
    Medical condition: Bacterial Vaginosis (BV)
    Disease: Version SOC Term Classification Code Term Level
    20.1 10021881 - Infections and infestations 10004055 Bacterial vaginosis PT
    Population Age: Adults Gender: Female
    Trial protocol: PL (Completed) HU (Completed)
    Trial results: (No results available)
    EudraCT Number: 2004-005173-27 Sponsor Protocol Number: 0858A4-318-WW Start Date*: 2005-10-21
    Sponsor Name:Wyeth Research Division of Wyeth Pharmaceuticals Inc., Clinical Research and Development
    Full Title: A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF A COMBINATION OF LEVONORGESTREL AND ETHINYL ESTRADIOL IN A CONTINUOUS DAILY REGIMEN IN SUBJECTS WITH PREMENSTRUAL DYSPHORIC DISO...
    Medical condition: Premenstrual dysphoric disorder (PMDD) affects 3% to 5% of menstruating women. PMDD is defined by markedly depressed mood, anxiety, and/or affective lability during the last week of the late lutea...
    Disease:
    Population Age: Adults Gender: Female
    Trial protocol: GB (Completed) FI (Completed) SE (Completed) DK (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2018-002190-21 Sponsor Protocol Number: MAR-BAS-18-005 Start Date*: 2020-07-08
    Sponsor Name:Fondazione per la Medicina Personalizzata
    Full Title: The ROME trial from histology to target: the road to personalize target therapy and immunotherapy
    Medical condition: Patients with progressive disease (recurrent and/or metastatic) of breast cancer, metastatic gastro-intestinal tumors, non small cell lung cancer (NSCLC) or others. Patients should have completed a...
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10066275 Comedocarcinoma of breast LLT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10007351 Carcinoma gastrointestinal LLT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10071533 Lung squamous cell carcinoma metastatic PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Fri May 16 14:03:45 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA